Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epicyte Pharmaceutical Inc.

Division of Biolex Therapeutics Inc.

Latest From Epicyte Pharmaceutical Inc.

ProdiGene Inc.

ProdiGene Inc. was the first company to commercialize recombinant proteins from transgenic plants. It has used its head start to assemble a strong IP portfolio and form a number of strategic partnerships to advance its programs in proteins for biopharmaceutical and industrial applications. Using corn as its production vehicle, ProdiGene is close to hitting the market with an industrial enzyme, and will embark soon on clinical trials for edible human vaccines for e.coli and hepatitis B.
BioPharmaceutical Manufacturing

Protein Harvest

Genetic engineering is giving a new meaning to the term "manufacturing plant" as the biotechnology industry looks to potatoes, corn, tobacco, and other crops to provide cheap manufacturing sources for therapeutic The lack of capacity for the cost-effective manufacture of protein-based pharmaceuticals will soon cause a significant bottleneck at pharmaceutical companies, one that threatens to impede the progress of therapeutics at all stages of development, from the preclinical stage to commercialization. Today, companies are faced with the limited options of either queuing up for outsourced manufacturing, or investing hundreds of millions of dollars in their own production capacity well before they know that a product will succeed. A bumper crop of new companies is therefore poised to take advantage of the manufacturing capabilities of plants that have been genetically engineered to produce human proteins.
BioPharmaceutical Manufacturing

Antibody Opportunities

Antibodies are driving valuations at many public companies--and the aspirations of start-ups with new means of generating, tailoring and harnessing the proteins.
BioPharmaceutical Strategy

Leveraging Antibodies

Human antibodies are hot. Three leading companies with patented means for making them are battling for partners and strategic position, anxious to sign alliances before current competitors muscle in, or next-generation technologies come along. Abgenix and Medarex effectively share a duopoly on transgenic mice that make human antibodies. Both firms license their technologies on an antigen-by-antigen basis, but are moving to build more value by deploying the methods on their own behalf, and via 50/50 deals with companies willing to share targets and development costs. Cambridge Antibody Technology is the leading promoter of phage-display technology, a bacterially-based, relatively high throughput method of making human antibody fragments that can be used as reagents to validate targets, or built up into drugs. Owning products is the end-game for all three players. But their approaches to the goal differ, particularly in the way they're structuring deals and the number of products they intend to put into clinical development.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biolex Therapeutics Inc.
  • Senior Management
  • Lloyd M Kunimoto, CEO
    Christiane Sheid, CFO
    Andrew Hiatt, PhD, VP, Research
    Mich B Hein, PhD, Pres.
    Vincent Gotz, VP, Bus. Dev.
  • Contact Info
  • Epicyte Pharmaceutical Inc.
    Phone: (858) 554-0281
    5810 Nancy Ridge Dr., Ste. 150
    San Diego, CA 92121